Graft Rejection

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2009-02-13
EMA Withdrawn: Zenapax (daclizumab) — Roche Registration Ltd.
EMA has withdrawn Zenapax (daclizumab) from the market in January 2007.